Report #2896089

Received May 11, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: Age unknown
State: AZ
Recovered: Recovered
Vaccinated: Jan 1, 2026
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	1	—	—

Symptoms (1)

Herpes zoster

Symptom narrative

Developed shingles; This non-serious case was reported by a consumer via call center representative and described the occurrence of shingles in a male patient who received Herpes zoster (Shingrix) for prophylaxis. In JAN-2026, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced shingles (Verbatim: Developed shingles). The outcome of the shingles was resolved (duration 1 month). It was unknown if the reporter considered the shingles to be related to Shingrix. It was unknown if the company considered the shingles to be related to Shingrix. Additional Information: GSK receipt date: 24-APR-2026 The patient was called regarding his second dose of Shingrix stating he received his first dose toward the end of JAN-2026 (sometime between JAN 23-26) and developed shingles for about a month. He was now due for his second dose and has questions and concerns regarding developing shingles again. The batch number was not provided, and unable to contact the reporter.